Steffan Joe's Album: Wall Photos
The CAR-T therapies
market is characterized by a healthy pipeline of promising therapies, claims
Roots Analysis
Report Keywords - CAR-T Cell, Therapies
Market, Rootsanalysis, Report, Biotech
Given the success of
approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and
BREYANZI®, this upcoming class of biologics are anticipated to carve out a
significant share of the multi-billion dollar cancer immunotherapy market
Roots
Analysis has announced the addition of “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple
Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular
Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target
Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies
(North America, Europe, Asia Pacific, Latin America, Middle East and North
Africa, and Rest of the World) – Industry Trends and Global Forecasts,
2021-2030” report to its list of offerings.
Given their ability to selectively direct a cell mediated
immune response against cancer cells and, thereby, offer prolonged periods of
disease remission, several CAR-T cell therapies provide a promising therapeutic
strategy for advanced stage cancers and are expected to achieve blockbuster
status. With four approved products and many candidate therapies under
evaluation for the treatment of multiple disease indications, the CAR-T cell
therapy market is characterized by a healthy and growing pipeline. Further,
with lucrative financial support and notable increase in partnerships, the
CAR-T-cell therapies market is abuzz with activity.
To order this 795+ page report, which features
165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Key Market Insights
Over 755 CAR-T cell
therapies are currently approved
/ under development
Close to 40% of the aforementioned candidates are in
preclinical and discovery stages, while more than 25% are being evaluated in
clinical stages (phase I/II and above). Examples of late-stage clinical
candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T /
JNJ-68284528.
Currently, the focus is on developing product candidates to
treat various types of cancers
Over 95% of the products in the development pipeline are
being evaluated for the treatment of hematological malignancies, including (in
decreasing order of number of pipeline products) acute lymphoblastic
leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia.
Only 2% of current pipeline candidates are being developed for the treatment of
non-oncological indications.
Extensive efforts are underway to improve CAR constructs
Majority of the
product candidates in the clinical pipeline, including the four approved drug
products, are based on second generation CARs. Further, a number of novel therapies armed with fourth
generation CAR constructs, CAR-based products containing humanized scFv and
bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated
worldwide.
China is leading the product development efforts related to
CAR-T cell therapies, in terms of number of active trials and supporting
hospitals
In the last 10 years, over half of the 410 clinical trials
evaluating various types of CAR-T cell therapies, were registered in China. In
addition, owning to a favorable clinical research environment, China is
presently considered to be among the leading regions in the CAR-T cell therapy
space, with close to 40 industry players and more than 100 non-industry
players, including hospitals and universities, contributing to this field.
Partnership activity
within this domain has grown at a CAGR of 26%, between 2011 and 2020
More than 220 agreements were inked related to CAR-T cell
therapies, with the maximum activity being reported in 2018. Majority of
partnership deals signed within this domain were R&D agreements (21%),
technology licensing (20%) and product development and commercialization
agreements (11%).
Over USD 13 billion has been invested by both private and
public investors, across more than 205 instances
It is important to mention that, between 2013 and 2020,
majority of the funding was acquired through venture capital rounds (37%),
other equity financing elements (24%), grants (12%) and secondary offerings
(12%).
The market is anticipated to grow at a CAGR of over 28%,
during the period 2021-2030
Growth in this domain
is anticipated to be primarily driven by encouraging clinical trial results and
the recent success of the four approved CAR-T cell therapies. North America (primarily
the US) and Europe are expected to capture over 75% of the market share by
2030, in terms of the sales-based revenues.
To request a sample copy / brochure of
this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
Key
Questions Answered
§
Who are the leading industry and non-industry players in
this market?
§ What
are the prevalent R&D trends in CAR-T cell therapies domain?
§ What
are the key therapeutic areas for which CAR-T cell therapies are being / have
been developed?
§ What
are the challenges faced by stakeholders in this industry?
§ Which
are the key geographies where extensive research on CAR-T cell therapies is
being conducted?
§ Who
are the key investors in this domain?
§ Who
are the key opinion leaders / experts that can help in driving product development
efforts in this field?
§ What
kind of partnership models are commonly adopted by industry stakeholders?
§ What
kind of contract manufacturing support is available for CAR-T cell therapies?
§ What
kind of promotional strategies are likely to be adopted for CAR-T cell
therapies that are approved / commercialized in future?
§ What
are the factors that are likely to influence the evolution of this upcoming
market?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 14 billion (by 2030) financial opportunity
within the CAR-T cell therapy market has been analyzed across the following
segments:
§
Disease indication
§ Non-Hodgkin
lymphoma
§ Multiple
myeloma
§ Chronic
lymphocytic leukemia
§ Acute
lymphoblastic leukemia
§ Follicular
lymphoma
§ Mantle
cell lymphoma
§ Hepatocellular
carcinoma
§ Colorectal
cancer
§ Target
antigens
§ CD19
§ BCMA
§ CD19,
CD22
§ GPC3
§ EGFR
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia
Pacific
§ Latin
America
§ Middle
East and North Africa
§ Rest
of the World
The report features inputs from eminent industry
stakeholders, according to whom CAR-T cell therapies are soon likely to witness
increased adoption given their broad scope of applications in various advanced
stage oncological disorders. The report includes detailed transcripts
of discussions held with the following experts:
§
Tim Oldham (Chief Executive Officer, Cell Therapies)
§
Troels Jordansen (Chief Executive Officer, Glycostem
Therapeutics)
§
Wei (William) Cao (Co-Founder, Chairman and Chief Executive
Officer, Gracell Biotechnologies)
§
Miguel Forte (Chief Operating Officer, TxCell)
§
Adrian Bot (Vice President, Scientific Affairs, Kite
Pharma)
§
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
§
Brian Dattilo (Manager of Business Development, Waisman
Biomanufacturing)
§
Aino Kalervo (Competitive Intelligence Manager, Strategy
& Business Development, Theravectys)
§
Xian-Bao Zhan (Professor of Medicine and Director,
Department of Oncology, Changhai Hospital)
§
Enkhtsetseg Purev (Assistant Professor of Medicine,
University of Colorado)
The research includes brief profiles, featuring an overview
of the company, its financial information (if available), and a description of
its product(s), highlighting type of therapy and current development status.
Each company profile includes technology portfolio (if available), recent
developments related to T-cell immunotherapies and manufacturing capabilities
of the companies.
§
Autolus
§
bluebird bio
§
CARsgen Therapeutics
§
Celgene (A Bristol Myers Squibb Company)
§
Cellectis
§
Cellular Biomedicine Group
§
Innovative Cellular Therapeutics
§
Iovance Biotherapeutics
§
Kite Pharma (A Gilead Sciences Company)
§
Kuur Therapeutics
§
Noile-Immune Biotech
§
Novartis
§
Shanghai Genechem
§
Sinobioway Cell Therapy
§
Takara Bio
§
Ziopharm Oncology
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Global T-Cell Therapies Market (5th
Edition), 2021 – 2030
2.
mRNA Therapeutics and
Vaccines Market, 2020-2030
3. Gene Therapies Market (4th Edition):
Industry Trends and Global Forecasts, 2020-2030
4.
Oncolytic Virus Therapy Market:
Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
market is characterized by a healthy pipeline of promising therapies, claims
Roots Analysis
Report Keywords - CAR-T Cell, Therapies
Market, Rootsanalysis, Report, Biotech
Given the success of
approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and
BREYANZI®, this upcoming class of biologics are anticipated to carve out a
significant share of the multi-billion dollar cancer immunotherapy market
Roots
Analysis has announced the addition of “CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple
Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular
Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target
Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies
(North America, Europe, Asia Pacific, Latin America, Middle East and North
Africa, and Rest of the World) – Industry Trends and Global Forecasts,
2021-2030” report to its list of offerings.
Given their ability to selectively direct a cell mediated
immune response against cancer cells and, thereby, offer prolonged periods of
disease remission, several CAR-T cell therapies provide a promising therapeutic
strategy for advanced stage cancers and are expected to achieve blockbuster
status. With four approved products and many candidate therapies under
evaluation for the treatment of multiple disease indications, the CAR-T cell
therapy market is characterized by a healthy and growing pipeline. Further,
with lucrative financial support and notable increase in partnerships, the
CAR-T-cell therapies market is abuzz with activity.
To order this 795+ page report, which features
165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Key Market Insights
Over 755 CAR-T cell
therapies are currently approved
/ under development
Close to 40% of the aforementioned candidates are in
preclinical and discovery stages, while more than 25% are being evaluated in
clinical stages (phase I/II and above). Examples of late-stage clinical
candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T /
JNJ-68284528.
Currently, the focus is on developing product candidates to
treat various types of cancers
Over 95% of the products in the development pipeline are
being evaluated for the treatment of hematological malignancies, including (in
decreasing order of number of pipeline products) acute lymphoblastic
leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia.
Only 2% of current pipeline candidates are being developed for the treatment of
non-oncological indications.
Extensive efforts are underway to improve CAR constructs
Majority of the
product candidates in the clinical pipeline, including the four approved drug
products, are based on second generation CARs. Further, a number of novel therapies armed with fourth
generation CAR constructs, CAR-based products containing humanized scFv and
bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated
worldwide.
China is leading the product development efforts related to
CAR-T cell therapies, in terms of number of active trials and supporting
hospitals
In the last 10 years, over half of the 410 clinical trials
evaluating various types of CAR-T cell therapies, were registered in China. In
addition, owning to a favorable clinical research environment, China is
presently considered to be among the leading regions in the CAR-T cell therapy
space, with close to 40 industry players and more than 100 non-industry
players, including hospitals and universities, contributing to this field.
Partnership activity
within this domain has grown at a CAGR of 26%, between 2011 and 2020
More than 220 agreements were inked related to CAR-T cell
therapies, with the maximum activity being reported in 2018. Majority of
partnership deals signed within this domain were R&D agreements (21%),
technology licensing (20%) and product development and commercialization
agreements (11%).
Over USD 13 billion has been invested by both private and
public investors, across more than 205 instances
It is important to mention that, between 2013 and 2020,
majority of the funding was acquired through venture capital rounds (37%),
other equity financing elements (24%), grants (12%) and secondary offerings
(12%).
The market is anticipated to grow at a CAGR of over 28%,
during the period 2021-2030
Growth in this domain
is anticipated to be primarily driven by encouraging clinical trial results and
the recent success of the four approved CAR-T cell therapies. North America (primarily
the US) and Europe are expected to capture over 75% of the market share by
2030, in terms of the sales-based revenues.
To request a sample copy / brochure of
this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
Key
Questions Answered
§
Who are the leading industry and non-industry players in
this market?
§ What
are the prevalent R&D trends in CAR-T cell therapies domain?
§ What
are the key therapeutic areas for which CAR-T cell therapies are being / have
been developed?
§ What
are the challenges faced by stakeholders in this industry?
§ Which
are the key geographies where extensive research on CAR-T cell therapies is
being conducted?
§ Who
are the key investors in this domain?
§ Who
are the key opinion leaders / experts that can help in driving product development
efforts in this field?
§ What
kind of partnership models are commonly adopted by industry stakeholders?
§ What
kind of contract manufacturing support is available for CAR-T cell therapies?
§ What
kind of promotional strategies are likely to be adopted for CAR-T cell
therapies that are approved / commercialized in future?
§ What
are the factors that are likely to influence the evolution of this upcoming
market?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 14 billion (by 2030) financial opportunity
within the CAR-T cell therapy market has been analyzed across the following
segments:
§
Disease indication
§ Non-Hodgkin
lymphoma
§ Multiple
myeloma
§ Chronic
lymphocytic leukemia
§ Acute
lymphoblastic leukemia
§ Follicular
lymphoma
§ Mantle
cell lymphoma
§ Hepatocellular
carcinoma
§ Colorectal
cancer
§ Target
antigens
§ CD19
§ BCMA
§ CD19,
CD22
§ GPC3
§ EGFR
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia
Pacific
§ Latin
America
§ Middle
East and North Africa
§ Rest
of the World
The report features inputs from eminent industry
stakeholders, according to whom CAR-T cell therapies are soon likely to witness
increased adoption given their broad scope of applications in various advanced
stage oncological disorders. The report includes detailed transcripts
of discussions held with the following experts:
§
Tim Oldham (Chief Executive Officer, Cell Therapies)
§
Troels Jordansen (Chief Executive Officer, Glycostem
Therapeutics)
§
Wei (William) Cao (Co-Founder, Chairman and Chief Executive
Officer, Gracell Biotechnologies)
§
Miguel Forte (Chief Operating Officer, TxCell)
§
Adrian Bot (Vice President, Scientific Affairs, Kite
Pharma)
§
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
§
Brian Dattilo (Manager of Business Development, Waisman
Biomanufacturing)
§
Aino Kalervo (Competitive Intelligence Manager, Strategy
& Business Development, Theravectys)
§
Xian-Bao Zhan (Professor of Medicine and Director,
Department of Oncology, Changhai Hospital)
§
Enkhtsetseg Purev (Assistant Professor of Medicine,
University of Colorado)
The research includes brief profiles, featuring an overview
of the company, its financial information (if available), and a description of
its product(s), highlighting type of therapy and current development status.
Each company profile includes technology portfolio (if available), recent
developments related to T-cell immunotherapies and manufacturing capabilities
of the companies.
§
Autolus
§
bluebird bio
§
CARsgen Therapeutics
§
Celgene (A Bristol Myers Squibb Company)
§
Cellectis
§
Cellular Biomedicine Group
§
Innovative Cellular Therapeutics
§
Iovance Biotherapeutics
§
Kite Pharma (A Gilead Sciences Company)
§
Kuur Therapeutics
§
Noile-Immune Biotech
§
Novartis
§
Shanghai Genechem
§
Sinobioway Cell Therapy
§
Takara Bio
§
Ziopharm Oncology
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Global T-Cell Therapies Market (5th
Edition), 2021 – 2030
2.
mRNA Therapeutics and
Vaccines Market, 2020-2030
3. Gene Therapies Market (4th Edition):
Industry Trends and Global Forecasts, 2020-2030
4.
Oncolytic Virus Therapy Market:
Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis